[Articles] Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Related Posts

• Comparing Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Metastatic Breast Cancer Phase 3 Trial

  KEY TAKEAWAYS The DESTINY-Breast03 is a randomized, open-label, Phase 3 trial that evaluated the efficacy…

• Blocking soluble TNF{alpha} sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

  Background The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets…

• Combined Efficacy of Tucatinib and Trastuzumab for HER2-Positive MBTC

  KEY TAKEAWAYS The phase II trial aimed to evaluate the combined efficacy and safety of…